Publikationen in Zusammenarbeit mit Forschern von Charité (16)

2024

  1. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1016-1027

2023

  1. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

    Frontiers in Pharmacology

  2. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

    European Radiology, Vol. 33, Núm. 1, pp. 493-500

  3. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

  4. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    Frontiers in Pharmacology, Vol. 14

2022

  1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726

  2. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485

  3. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

    Frontiers in Gastroenterology, Vol. 1

  4. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

    Cancer Imaging, Vol. 22, Núm. 1

  5. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria

    Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 75, Núm. 6, pp. 1387-1396

  3. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

    EJNMMI Research, Vol. 11, Núm. 1

2019

  1. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 71, Núm. 6, pp. 1164-1174

2015

  1. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC

    Liver International, Vol. 35, Núm. 2, pp. 620-626

2014

  1. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity

    PLoS ONE, Vol. 9, Núm. 11